comparemela.com

Latest Breaking News On - மருந்து கண்டுபிடிப்பு முயற்சிகள் - Page 1 : comparemela.com

Opinion | In the Race for a Covid-19 Pill, a Little Lab Plays a Big Role

Mr. Adams is a journalist in Atlanta who has written about the pharmaceutical industry. ATLANTA Nine years ago, Dr. Dennis Liotta, a professor of organic chemistry at Emory University, set out to change the way drugs are developed for so-called neglected diseases those that primarily affect populations in poorer countries and for which there exist few, if any, safe and effective treatments. “The cold hard truth is that it can cost billions of dollars and take decades to develop a new drug,” he said during a TEDx talk in 2016, shortly after the World Health Organization had declared the Zika virus a neglected disease that had long been overlooked in the African countries where it is endemic an international public health emergency. “So pharmaceutical companies almost invariably only pursue drugs for diseases that will generate large profits.”

VIC Technology Venture Development Announces New Additions to Strategic Advisory Board, Bringing Together Industry Veterans to Guide Medical Innovation

VIC Technology Venture Development Announces New Additions to Strategic Advisory Board, Bringing Together Industry Veterans to Guide Medical Innovation Share Article Dr. Dennis Liotta and Dr. Paul Atkins “They are both innovative, life science veterans that have taken impactful technologies from the earliest stage to highly successful exits and we are fortunate to have them on our team.” said Calvin Goforth, Chief Executive Officer of VIC. FAYETTEVILLE, Ark. (PRWEB) May 17, 2021 VIC Technology Venture Development, which creates and develops high impact life science companies based on technologies exclusively licensed from top research institutions worldwide, announced today two new distinguished additions to their Strategic Advisory Board from across the life science industry.

American Pharma Company Making Oral Drug To Treat Non-Hospitalised Covid-19 Patients Enters Into Agreement With Five Indian Manufacturers

by Swarajya Staff - May 3, 2021 08:17 AM Merck Pharma Snapshot Molnupiravir is currently undergoing a phase-3 trial for the treatment of non-hospitalised patients with confirmed Covid-19. An experimental oral antiviral drug called molnupiravir, manufactured by the American pharmaceutical company, Merck, is expected to help stem the cases of coronavirus in India. The company, which is also known as MSD outside the United States and Canada, announced earlier last week that it has entered into non-exclusive voluntary licensing agreements for the drug with five established Indian generics manufacturers. Even though there are two Covid-19 vaccines in India—Covaxin and Covishield— it is believed that molnupiravir would play a key role in fighting the massive health crisis in the country.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.